Clinical pharmacogenetics of antiaggregants: clinical pharmacologist' point of view

QR Code

Clinical pharmacogenetics of antiaggregants: clinical pharmacologist' point of view

The review is devoted to individual antiaggregant sensitivity issue. According to numerous studies' data, acetylsalicylic acid is ineffective in 5 % of the patients. It might be explained by target molecule (COG-1) gene polymorphism. This phenomenon has important clinical implications, as aspir...

Full description

Saved in:

Bibliographic Details
Main Authors:	D. A. Syche, A. V. Zyatenkov, B. G. Kukes
Format:	Article
Language:	Russian
Published:	«FIRMA «SILICEA» LLC 2007-08-01
Series:	Российский кардиологический журнал
Subjects:	pharmacogenetics antiaggregants coronary heart disease acetylsalicylic acid clopidogrel iibfiiia receptor inhibitors
Online Access:	https://russjcardiol.elpub.ru/jour/article/view/2207
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Zyllt in coronary atherosclerosis patients after coronary artery bypass graft surgery. Preliminary results of an open, randomized, comparative ZEUS Study
by: Y. I. Grinstein, et al.
Published: (2008-12-01)

Clopidogrel in cardiovascular disease treatment: modern clinical recommendations
by: I. S. Yavelov
Published: (2006-10-01)

Antiplatelet drug resistance in patients with coronary heart disease
by: V. A. Sulimov, et al.
Published: (2012-12-01)

ANTITHROMBOTIC ACTIVITY OF SBT-828 COMPOUND
by: V. S. Sirotenko, et al.
Published: (2015-09-01)

ACETYLSALICYLIC ACID IN LOW DOSES FOR SECONDARY PREVENTION OF CARDIO-VASCULAR COMPLICATIONS
by: N. A. Dmitrieva, et al.
Published: (2016-01-01)

ANTIAGGREGANT THERAPY AND REDUCTION OF HIGH RESIDUAL PLATELET REACTIVITY
by: N. A. Mazur, et al.
Published: (2012-08-01)

ANTITHROMBOTIC THERAPY OF ISCHEMIC HEART DISEASE: FROM FAST ACTING ANTIAGGREGANTS TO STATINES AND NITRATE OXIDE. IS IT REAL?
by: I. A. Latfullin, et al.
Published: (2016-01-01)

CYP2C19 PHARMACOGENETIC TESTING FOR PERSONALIZATION OF ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME IN ROUTINE CLINICAL PRACTICE
by: A. I. Akhmetova, et al.
Published: (2017-12-01)

THE SIGNIFICANCE OF PHARMACOGENETIC CYP2C19 TESTING FOR PERSONALIZATION OF THE ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE
by: K. B. Mirzaev, et al.
Published: (2015-09-01)

Zyllt and acetylsalicylic acid in coronary atherosclerosis patients after coronary artery bypass graft intervention. Main results of the ZEUS Study: medication effectiveness, acetylsalicylic acid resistance mechanisms, short and long-term clinical outcomes
by: Yu. I. Grinstein, et al.
Published: (2009-08-01)

Gastrointestinal Bleeding in Antithrombotic Therapy in Patients with Coronary Heart Disease: Risk Factors, Pathogenesis and Treatment
by: N. S. Lapina, et al.
Published: (2020-07-01)

High residual platelet reactivity during dual antiplatelet therapy, found by optical aggregometry and the rate of atherothrombotic complications after coronary artery stenting in patients with ischemic heart disease in clinical practice
by: N. F. Puchinyan, et al.
Published: (2016-09-01)

CLOPIDOGREL FOR SELECTIVE MYOCARDIAL REVASCULARIZATION
by: N. V. Teplova
Published: (2016-03-01)

PHARMACOGENETIC BASES OF INDIVIDUAL SENSITIVITY AND PERSONALIZED ADMINISTRATION OF ANTIPLATELET THERAPY IN DIFFERENT ETHNIC GROUPS
by: B. I. Kantemirova, et al.
Published: (2021-05-01)

Therapeutic resistance in depression from the genetics and pharmacogenetics point of view
by: G. E. Mazo, et al.
Published: (2019-12-01)

Clopidogrel therapy effects on cell hemostasis in acute coronary syndrome
by: R. A. Rakhimova, et al.
Published: (2008-12-01)

ANTIPLATELET THERAPY RESISTANCE IN PATIENTS WITH ACUTE CORONARY SYNDROME WITH ST-SEGMENT ELEVATION
by: D. H. Ainetdinova, et al.
Published: (2016-01-01)

EFFECTS OF ACETYLSALICYLIC ACID AND CLOPIDOGREL ON MORPHOFUNCTIONAL STATUS OF ERYTHROCYTES IN PATIENTS WITH ACUTE CORONARY SYNDROME
by: A. L. Alyavi, et al.
Published: (2016-01-01)

THE SELECTION PROBLEMS OF ANTITHROMBOTIC THERAPY IN NONVALVULAR ATRIAL FIBRILLATION WITH COMORBIDITIES
by: N. A. Koziolova, et al.
Published: (2015-08-01)

RESISTANCE TO ANTIPLATELET DRUGS IN PATIENTS WITH ISCHEMIC HEART DISEASE
by: D. H. Aynetdinova, et al.
Published: (2015-12-01)

ANTIPLATELET DRUGS RESISTANCE IN PATIENTS WITH ISCHEMIC HEART DISEASE AND OBLITERATIVE ATHEROSCLEROSIS OF LOWER LIMB ARTERIES ASSOCIATED WITH DIABETES MELLITUS TYPE 2
by: E. V. Gorjacheva, et al.
Published: (2016-01-01)

RESIDUAL PLATELET REACTIVITY DURING THERAPY WITH INHIBITORS OF CYCLOOXIGENASE OR ADENOSINE DIPHOSPHATE RECEPTORS
by: A. A. Lomonosova, et al.
Published: (2015-12-01)

Molecular and metabolic characteristics of changes in the platelet sensitivity to antiplatelet therapy in patients with coronary artery disease before and after coronary artery bypass grafting
by: M. D. Goncharov, et al.
Published: (2021-07-01)

ACETYLSALICYLIC ACID AND PREVENTION OF FATAL OUTCOMES IN CARDIOVASCULAR DISEASE: SELECTING MEDICATION FORM AND DOSE
by: O. V. Averkov
Published: (2012-08-01)

Pharmacogenetic and Clinical Predictors of Clopidogrel Insufficiency in a Patient with Atherosclerosis Obliterans of the Lower Extremities: Clinical Case
by: M. A. Andreyanova, et al.
Published: (2018-11-01)

CLOPIDOGREL PHARMACOGENETICS
by: A. N. Meshkov
Published: (2016-01-01)

Pharmacogenetic substantiation of personalized prescription of oral anticoagulants in clinical practice
by: K.I. Bentsionova, et al.
Published: (2023-03-01)

Multi-Ethnic Analysis of Cardiac Pharmacogenetic Markers of Cytochrome P450 and Membrane Transporters Genes in the Russian Population
by: K. B. Mirzaev, et al.
Published: (2019-07-01)

Antiaggregant influence on platelet aggregation in patients with acute coronary syndrome without ST segment elevation
by: T. M. Poponina, et al.
Published: (2006-10-01)

Experimental study of systemic hemostatic effects of fibrin monomer in inhibition of platelet aggregation function
by: V. M. Vdovin, et al.
Published: (2020-04-01)

Additional evidence against widespread use of inpatient antiplatelet therapy in coronavirus infection: data from a randomized controlled trial
by: I. S. Yavelov
Published: (2022-02-01)

Pharmacists’ perspectives on integrating pharmacogenetics in clinical practice
by: Najmaddin A. H. Hatem, et al.
Published: (2025-06-01)

Early discontinuation of dual antiplatelet therapy via acetylsalicylic acid cessation in patients with acute coronary syndrome undergoing percutaneous coronary interventions to reduce the bleeding risk
by: O. V. Averkov
Published: (2021-02-01)

The pharmacogenetics antiepileptic drugs
by: N. A. Shnayder, et al.
Published: (2008-12-01)

Morphological determinants for the local hemostatic effect of exogenous fibrin monomer in its systemic administration after injury with inhibition of platelet aggregation in the experiment
by: V. M. Vdovin, et al.
Published: (2023-10-01)

INFLUENCE OF THE CYP3A4 ISOENZYME METABOLIC ACTIVITY AND CYP2C19 GENE POLYMORPHISMS ON CLOPIDOGREL ANTIPLATELET EFFECT IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION
by: K. B. Mirzaev, et al.
Published: (2015-09-01)

ANALGETICS-ANTIPYRETICS IN PEDIATRICIAN’S PRACTICE: THE POINT OF VIEW OF CLINICAL PHARMACOLOGIST
by: G.G. Ketova
Published: (2009-11-01)

Clopidogrel effects on thrombolysis effectiveness and clinical course of ST elevation myocardial infarction (30-day follow-up)
by: S. V. Shalaev, et al.
Published: (2007-08-01)

PRACTICAL ASPECTS OF APIXABAN USE IN CLINICAL PRACTICE: VIEW POINT OF CLINICAL PHARMACOLOGIST
by: D. A. Sychev, et al.
Published: (2015-09-01)

SUPPRESSION OF RENIN-ANGIOTENSIN SYSTEM TO PREVENT COMPLICATIONS OF CARDIOVASCULAR DISEASES: CURRENT "ROLES" DISTRIBUTION FROM CLINICAL PHARMACOLOGIST’S POINT OF VIEW
by: S. R. Gilyarevskiy, et al.
Published: (2016-01-01)